HOXB-AS3: A Potential Drug Target and Biomarker (G404266)

Target Name: HOXB-AS3

NCBI ID: G404266

HOXB-AS3

Other Name(s): HOXB cluster antisense RNA 3 | HOXB cluster antisense RNA 3, transcript variant 1 | HOXB-AS3 variant 1

HOXB-AS3: A Potential Drug Target and Biomarker

Hoxb-AS3, also known as HOXB cluster antisense RNA 3, is a non-coding RNA molecule that has been identified as a potential drug target or biomarker. The Hoxb-AS3 gene is located on chromosome 6 and encodes a 24 amino acid protein known as HOXB. HOXB is a member of the Hox gene family, which is known to play a critical role in the development and maintenance of tissues and organs during development and throughout life.

HOXB-AS3: A Putative Drug Target

HOXB-AS3 has been identified as a potential drug target due to its involvement in various cellular processes that are relevant to human disease. One of the key functions of HOXB is to regulate cell growth and differentiation, which is crucial for the development and maintenance of tissues and organs during development and throughout life. HOXB-AS3 has been shown to play a role in the regulation of cell proliferation, apoptosis, and autophagy, which are all important processes that are involved in the control of cell growth and function.

In addition to its role in cell growth and differentiation, HOXB-AS3 has also been shown to be involved in the regulation of cellular signaling pathways. HOXB-AS3 has been shown to play a role in the regulation of the PI3K/Akt signaling pathway, which is a critical pathway involved in the regulation of cellular signaling pathways that are involved in a wide range of cellular processes, including cell survival, growth, and differentiation.

HOXB-AS3 as a Potential Biomarker

HOXB-AS3 has also been identified as a potential biomarker for a variety of human diseases. For example, HOXB-AS3 has been shown to be significantly decreased in the blood samples of patients with various types of cancer, including breast, lung, and colorectal cancers. Additionally, HOXB-AS3 has been shown to be decreased in the urine samples of patients with urological and renal cancers. These findings suggest that HOXB-AS3 may be a useful biomarker for the diagnosis and prognosis of various types of cancer.

HOXB-AS3 has also been shown to be involved in the regulation of cellular pathways that are involved in the development and progression of neurodegenerative diseases. For example, HOXB-AS3 has been shown to play a role in the regulation of the TGF-β pathway, which is a critical pathway involved in the development and progression of many neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Conclusion

HOXB-AS3 is a non-coding RNA molecule that has been identified as a potential drug target or biomarker. HOXB-AS3 is involved in various cellular processes that are relevant to human disease, including cell growth and differentiation, signaling pathways, and the regulation of cellular pathways that are involved in the development and progression of neurodegenerative diseases. Further research is needed to determine the role of HOXB-AS3 in human disease and to develop it as a potential drug target or biomarker.

Protein Name: HOXB Cluster Antisense RNA 3

Functions: Blocks the binding of HNRNPA1 to the intronic sequences flanking exon 9 of the PKM gene by competitively binding to the HNRNPA1 RGG-box motif (PubMed:28985503). This inhibits inclusion of exon 9 and promotes inclusion of exon 10, suppressing formation of the PKM M2 isoform and promoting production of the M1 isoform (PubMed:28985503). Also suppresses HNRNPA1-mediated processing of microRNA 18a (miR-18a) (PubMed:28985503). Promotes MYC stability through interaction with IGF2BP2 (PubMed:34457052)

The "HOXB-AS3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HOXB-AS3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets